Covered recipient · General Payments record
JONATHAN P RICHARD
Allopathic & Osteopathic Physicians Internal Medicine
General Payments · PY2018–2024
$1,603.20
- Reported across 82 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $295.90 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Amgen Inc. | $78.35 | 5 |
| PFIZER INC. | $69.97 | 3 |
| Antares Pharma, Inc. | $42.18 | 2 |
| Azurity Pharmaceuticals, Inc. | $35.45 | 2 |
| Lilly USA, LLC | $30.52 | 2 |
| Acerta Pharma LLC | $20.82 | 1 |
| Endo USA, Inc. | $18.61 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Amgen Inc. | $15.71 | 01/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117364205 | CMS |
| Amgen Inc. | $17.23 | 02/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117364207 | CMS |
| Amgen Inc. | $15.71 | 05/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117364209 | CMS |
| Amgen Inc. | $14.85 | 11/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111687868 | CMS |
| Amgen Inc. | $14.85 | 11/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117364211 | CMS |
| Antares Pharma, Inc. | $24.52 | 07/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146481374 | CMS |
| Antares Pharma, Inc. | $17.66 | 10/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146481379 | CMS |
| AstraZeneca Pharmaceuticals LP | $20.82 | 02/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105737203 | CMS |
| Azurity Pharmaceuticals, Inc. | $15.02 | 05/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1134011711 | CMS |
| Azurity Pharmaceuticals, Inc. | $20.43 | 10/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1134011713 | CMS |
| Endo USA, Inc. | $18.61 | 10/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1138586862 | CMS |
| Lilly USA, LLC | $13.64 | 06/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135096644 | CMS |
| Lilly USA, LLC | $16.88 | 10/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135096646 | CMS |
| PFIZER INC. | $23.65 | 06/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132010120 | CMS |
| PFIZER INC. | $24.40 | 08/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132010118 | CMS |
| PFIZER INC. | $21.92 | 09/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1130883472 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.